Impact of a pharmacist intervention at an intensive care rehabilitation clinic

MacTavish, Pamela; Quasim, Tara; Shaw, Martin; Devine, Helen; Daniel, Malcolm; Kinsella, John; Fenelon, C.; Kishore, R.; Iwashyna, Theodore J.; McPeake, Joanne

doi:10.1136/bmjoq-2018-000580

Cited by 16 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intensive Care Syndrome: Promoting Independence and Return to Employment (InS:PIRE) is a 5-week rehabilitation program for ICU survivors. Previous research has described this program ( 4 – 6 ). Participants were invited between 4 and 12 weeks after hospital discharge.…”

Section: Methodsmentioning

confidence: 99%

Medication-related Problems in Intensive Care Unit Survivors: Learning from a Multicenter Program

et al. 2020

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Medication-related Problems in Intensive Care Unit Survivors: Learning from a Multicenter Program

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…Because intensive care units (ICUs) are complex for patients and medications, the risk of prescribing errors and related adverse drug events (ADE) is high 1–3 . An adverse drug event, on the other hand, may be associated with the need for extra treatment, extended hospital stay, morbidity and mortality, and causes extra healthcare costs 2,4 .…”

Section: What Is Known and Objectivementioning

confidence: 99%

The effect of the clinical pharmacist in minimizing drug‐related problems and related costs in the intensive care unit in Turkey: A non‐randomized controlled study

AYHAN

Karakurt

Sancar

2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objective: Drug-related problems (DRPs) are common in hospitalized patients in intensive care unit (ICU). The aim of the study is to reduce DRPs and associated costs with clinical pharmacist's (CP) recommendations. Methods:The study is a prospective, non-randomized controlled study conducted in the ICU for a total of 6 months (1 January 2021-30 June 2021) in 2-month control, 2-month study, and 2-month control periods. Patients who were hospitalized for more than 24 h and used more than one medication were included in the study. The PCNE V9.1 Classification system was used in the classification of DRPs. During the intervention period, CP recommendations for DRPs were proposed to the healthcare team.Results and discussion: A total of 146 patients were included in the study. A total of 1061 DRPs from all periods were detected. The most common causes of DRPs were potential drug-drug interactions (31.76%), high dose (12.44%), and dose timing instruction errors (9.24%). For 347 DRPs identified during the study period, 259 interventions (74.63%) were recommended, and 238 (91.89%) were accepted by physicians. Interventions were mostly made as interrupting/discontinuing the drug (28.02%), changing the dose (25.27%), changing the instructions for use (20.32%), and starting a new drug (15.93%). Cost savings were achieved with CP recommendations applied.What is new and conclusion: The CP's recommendations were highly accepted by the healthcare team. With the CP's participation in routine patient rounds in the healthcare team of the ICU, drug-related costs would also decrease.

show abstract

“…Clinical pharmacy services to patient care based on pharmaceutical care principles contribute to improved therapeutic outcomes and the resolution of drug‐related issues such as drug compliance with indications, doses, side effects/toxicity, blood level monitoring, route of administration, interactions, and incompatibilities 5 . Studies also have shown that the frequency of AKI and other drug‐related problems observed in the clinic decreases with the involvement of the clinical pharmacist in the healthcare team 6–9 . However, no study is available in the literature showing the role of the clinical pharmacist in the prevention of AKI that can be observed in patients treated in the ICU and in improving the clinical outcomes of AKI.…”

Section: What Is Known and Objectivementioning

confidence: 99%

The role of the clinical pharmacist in the prevention of drug‐induced acute kidney injury in the intensive care unit

Polat

Koç

Demirkan

2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What Is Known and Objective: Acute kidney injury (AKI) is a disorder that is commonly seen in patients in the intensive care unit (ICU) and has a detrimental impact on the patients' clinical prognosis. Although a variety of factors contribute to the development of AKI in patients, drug-induced AKI is a common occurrence in the ICU. With the widespread availability of clinical pharmacy services, the clinical pharmacist's consultation service to the healthcare team aids in the resolution of drugrelated issues and the enhancement of therapeutic outcomes. The involvement of a clinical pharmacist in the ICU team is expected to minimize the incidence of druginduced AKI and enhance therapeutic results. Therefore, the goal of our study was to demonstrate the impact of having a clinical pharmacist on the occurrence, stages, and treatment of AKI. Methods: The study included two patient groups: intervention (n = 75) (IG) and control (n = 75) (CG) groups. The clinical pharmacist has made recommendations to the ICU team regarding the treatment of IG patients on drug selection, drug administration routes, drug dose adjustment, drug-drug interactions, drug-food or nutritional solution interactions, drug side effect management, and drug incompatibility. No interventions were provided by the clinical pharmacist in the CG patients. The clinical pharmacist visited patients regularly and noted the laboratory findings and pharmacological treatments of patients in the study groups on the patient follow-up forms.The obtained data of IG and CG were compared and statistical methods were used to assess them.Results and Discussion: According to our findings, AKI was found to be more common in CG than in IG (p < 0.05). Stage 1 was shown to be the most common AKI stage in the patients (p > 0.05). The gap between the patients' highest Cr and basal sCr values was less in IG (p < 0.05). When the association between reasons for ICU admission and AKI was investigated, pulmonary edema and acute respiratory failure were found to have a significant and positive relationship with AKI (p < 0.05). Furthermore, it was shown that patients with diabetes and cancer comorbidities were the most vulnerable to developing AKI (p < 0.05). Antibiotics, anaesthetics, and cardiovascular system medication categories were found to have a significant and positive correlation with AKI in patients (p < 0.05). Also, it was revealed that the usage of vancomycin, colistin, ampicillin-sulbactam, clarithromycin, ceftriaxone, midazolam, and dexketoprofen caused AKI (p < 0.05).

show abstract

Impact of a pharmacist intervention at an intensive care rehabilitation clinic

Cited by 16 publications

References 34 publications

Medication-related Problems in Intensive Care Unit Survivors: Learning from a Multicenter Program

Medication-related Problems in Intensive Care Unit Survivors: Learning from a Multicenter Program

The effect of the clinical pharmacist in minimizing drug‐related problems and related costs in the intensive care unit in Turkey: A non‐randomized controlled study

The role of the clinical pharmacist in the prevention of drug‐induced acute kidney injury in the intensive care unit

Contact Info

Product

Resources

About